238 related articles for article (PubMed ID: 30134961)
1. Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice.
Vitale F; Giliberto L; Ruiz S; Steslow K; Marambaud P; d'Abramo C
Acta Neuropathol Commun; 2018 Aug; 6(1):82. PubMed ID: 30134961
[TBL] [Abstract][Full Text] [Related]
2. Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model.
Nisbet RM; Van der Jeugd A; Leinenga G; Evans HT; Janowicz PW; Götz J
Brain; 2017 May; 140(5):1220-1230. PubMed ID: 28379300
[TBL] [Abstract][Full Text] [Related]
3. Passive Immunization in JNPL3 Transgenic Mice Using an Array of Phospho-Tau Specific Antibodies.
d'Abramo C; Acker CM; Jimenez H; Davies P
PLoS One; 2015; 10(8):e0135774. PubMed ID: 26270821
[TBL] [Abstract][Full Text] [Related]
4. Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice.
Liu W; Zhao L; Blackman B; Parmar M; Wong MY; Woo T; Yu F; Chiuchiolo MJ; Sondhi D; Kaminsky SM; Crystal RG; Paul SM
J Neurosci; 2016 Dec; 36(49):12425-12435. PubMed ID: 27927959
[TBL] [Abstract][Full Text] [Related]
5. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain.
Boutajangout A; Ingadottir J; Davies P; Sigurdsson EM
J Neurochem; 2011 Aug; 118(4):658-67. PubMed ID: 21644996
[TBL] [Abstract][Full Text] [Related]
6. Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds.
Castillo-Carranza DL; Gerson JE; Sengupta U; Guerrero-Muñoz MJ; Lasagna-Reeves CA; Kayed R
J Alzheimers Dis; 2014; 40 Suppl 1():S97-S111. PubMed ID: 24603946
[TBL] [Abstract][Full Text] [Related]
7. Intramuscular injection of vectorized-scFvMC1 reduces pathological tau in two different tau transgenic models.
Vitale F; Ortolan J; Volpe BT; Marambaud P; Giliberto L; d'Abramo C
Acta Neuropathol Commun; 2020 Aug; 8(1):126. PubMed ID: 32762731
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements.
Asuni AA; Boutajangout A; Quartermain D; Sigurdsson EM
J Neurosci; 2007 Aug; 27(34):9115-29. PubMed ID: 17715348
[TBL] [Abstract][Full Text] [Related]
9. Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice.
Ittner A; Bertz J; Suh LS; Stevens CH; Götz J; Ittner LM
J Neurochem; 2015 Jan; 132(1):135-45. PubMed ID: 25041093
[TBL] [Abstract][Full Text] [Related]
10. Transgenic mouse model of tau pathology in astrocytes leading to nervous system degeneration.
Forman MS; Lal D; Zhang B; Dabir DV; Swanson E; Lee VM; Trojanowski JQ
J Neurosci; 2005 Apr; 25(14):3539-50. PubMed ID: 15814784
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice.
Boimel M; Grigoriadis N; Lourbopoulos A; Haber E; Abramsky O; Rosenmann H
Exp Neurol; 2010 Aug; 224(2):472-85. PubMed ID: 20546729
[TBL] [Abstract][Full Text] [Related]
12. GFP-Mutant Human Tau Transgenic Mice Develop Tauopathy Following CNS Injections of Alzheimer's Brain-Derived Pathological Tau or Synthetic Mutant Human Tau Fibrils.
Gibbons GS; Banks RA; Kim B; Xu H; Changolkar L; Leight SN; Riddle DM; Li C; Gathagan RJ; Brown HJ; Zhang B; Trojanowski JQ; Lee VM
J Neurosci; 2017 Nov; 37(47):11485-11494. PubMed ID: 28986461
[TBL] [Abstract][Full Text] [Related]
13. Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology.
Leroy K; Ando K; Héraud C; Yilmaz Z; Authelet M; Boeynaems JM; Buée L; De Decker R; Brion JP
J Alzheimers Dis; 2010; 19(2):705-19. PubMed ID: 20110614
[TBL] [Abstract][Full Text] [Related]
14. Phos-tau peptide immunization of amyloid-tg-mice reduced non-mutant phos-tau pathology, improved cognition and reduced amyloid plaques.
Benhamron S; Rozenstein-Tsalkovich L; Nitzan K; Abramsky O; Rosenmann H
Exp Neurol; 2018 May; 303():48-58. PubMed ID: 29432723
[TBL] [Abstract][Full Text] [Related]
15. Targeting tauopathy with engineered tau-degrading intrabodies.
Gallardo G; Wong CH; Ricardez SM; Mann CN; Lin KH; Leyns CEG; Jiang H; Holtzman DM
Mol Neurodegener; 2019 Oct; 14(1):38. PubMed ID: 31640765
[TBL] [Abstract][Full Text] [Related]
16. TOC1: a valuable tool in assessing disease progression in the rTg4510 mouse model of tauopathy.
Ward SM; Himmelstein DS; Ren Y; Fu Y; Yu XW; Roberts K; Binder LI; Sahara N
Neurobiol Dis; 2014 Jul; 67():37-48. PubMed ID: 24631720
[TBL] [Abstract][Full Text] [Related]
17. Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis.
Selenica ML; Davtyan H; Housley SB; Blair LJ; Gillies A; Nordhues BA; Zhang B; Liu J; Gestwicki JE; Lee DC; Gordon MN; Morgan D; Dickey CA
J Neuroinflammation; 2014 Sep; 11():152. PubMed ID: 25183004
[TBL] [Abstract][Full Text] [Related]
18. Detecting tau in serum of transgenic animal models after tau immunotherapy treatment.
d'Abramo C; Acker CM; Schachter JB; Terracina G; Wang X; Forest SK; Davies P
Neurobiol Aging; 2016 Jan; 37():58-65. PubMed ID: 26508157
[TBL] [Abstract][Full Text] [Related]
19. Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity.
d'Abramo C; Acker CM; Jimenez HT; Davies P
PLoS One; 2013; 8(4):e62402. PubMed ID: 23638068
[TBL] [Abstract][Full Text] [Related]
20. Deficiency of terminal complement pathway inhibitor promotes neuronal tau pathology and degeneration in mice.
Britschgi M; Takeda-Uchimura Y; Rockenstein E; Johns H; Masliah E; Wyss-Coray T
J Neuroinflammation; 2012 Sep; 9():220. PubMed ID: 22989354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]